| Description |
ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
|
| Related Catalog |
|
| Target |
EP4
|
| In Vitro |
ONO-AE3-208 surpresses the in vitro cell invasion and migration in a dose-dependent manner without affecting cell proliferation[1]. ONO-AE3-208 abolisheS CTGF in the presence of the EET synthesis inhibitor MS-PPOH. Arachidonic acid (AA) causeS dose-dependent dilation of the attached Af-Art, and this effect is blocked by ONO-AE3-208[2].
|
| In Vivo |
ONO-AE3-208 surpresses the in vivo bone metastasis of PC3 cells in mice[1]. The photon tumor burdens are significantly increased in a time-dependent manner in the control group in comparison with those in the ONO-AE3-208-treated group. The rate of metastasis formation is significantly higher in the former than in the latter. The median time of metastasis formation is 29 d in the ONO-AE3-208-treated animals as compared with 21 d in the controls[3].
|
| References |
[1]. Xu S, et al. An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer. Cell Biochem Biophys. 2014 Apr 18. [2]. Ren Y, et al. Prostaglandin E2 mediates connecting tubule glomerular feedback. Hypertension. 2013 Dec;62(6):1123-8. [3]. Xu S, et al. Inhibitory effect of ONO-AE3-208 on the formation of bone metastasis of prostate cancer in mice. Zhonghua Nan Ke Xue. 2014 Aug;20(8):684-9. [4]. Thieme K, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep. 2017 Jun 13;7(1):3442.
|
